Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Clinical and neural responses to cognitive behavioral therapy for functional tremor.

Espay AJ, Ries S, Maloney T, Vannest J, Neefus E, Dwivedi AK, Allendorfer JB, Wulsin LR, LaFrance WC, Lang AE, Szaflarski JP.

Neurology. 2019 Oct 4. pii: 10.1212/WNL.0000000000008442. doi: 10.1212/WNL.0000000000008442. [Epub ahead of print]

PMID:
31586023
2.

Racial differences in adult-onset MRI-negative temporal lobe epilepsy.

Allen SE, Limdi NA, Westrick AC, Ver Hoef LW, Szaflarski JP, Kuzniecky RI, Knowlton RC.

Epilepsy Behav. 2019 Sep 28;100(Pt A):106501. doi: 10.1016/j.yebeh.2019.106501. [Epub ahead of print]

PMID:
31574425
3.

Sex, Age, and Handedness Modulate the Neural Correlates of Active Learning.

Nair S, Nenert RE, Allendorfer JB, Goodman AM, Vannest J, Mirman D, Szaflarski JP.

Front Neurosci. 2019 Sep 11;13:961. doi: 10.3389/fnins.2019.00961. eCollection 2019.

4.

Health literacy and quality of life in patients with treatment-resistant epilepsy.

Scrivner B, Szaflarski M, Baker EH, Szaflarski JP.

Epilepsy Behav. 2019 Aug 26;99:106480. doi: 10.1016/j.yebeh.2019.106480. [Epub ahead of print]

PMID:
31465909
5.

FMRI response to acute psychological stress differentiates patients with psychogenic non-epileptic seizures from healthy controls - A biochemical and neuroimaging biomarker study.

Allendorfer JB, Nenert R, Hernando KA, DeWolfe JL, Pati S, Thomas AE, Billeaud N, Martin RC, Szaflarski JP.

Neuroimage Clin. 2019 Aug 6;24:101967. doi: 10.1016/j.nicl.2019.101967. [Epub ahead of print]

6.

Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.

Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP, Szaflarski JP; UAB CBD Program.

Epilepsy Behav. 2019 Sep;98(Pt A):201-206. doi: 10.1016/j.yebeh.2019.07.008. Epub 2019 Aug 2.

PMID:
31382177
7.

Memory response and neuroimaging correlates of a novel cognitive rehabilitation program for memory problems in epilepsy: A pilot study.

Gaston TE, Nair S, Allendorfer JB, Martin RC, Beattie JF, Szaflarski JP.

Restor Neurol Neurosci. 2019 Jun 28. doi: 10.3233/RNN-190919. [Epub ahead of print]

PMID:
31282442
8.

fMRI Language Activation-If You See It Don't Resect It….

Szaflarski JP.

Epilepsy Curr. 2019 Jul-Aug;19(4):240-242. doi: 10.1177/1535759719856025. Epub 2019 Jun 21.

PMID:
31220938
9.

Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.

Martin RC, Gaston TE, Thompson M, Ampah SB, Cutter G, Bebin EM, Szaflarski JP.

Epilepsy Behav. 2019 Aug;97:105-110. doi: 10.1016/j.yebeh.2019.04.044. Epub 2019 Jun 18.

PMID:
31220785
10.

High health care costs in minority groups of older US Medicare beneficiaries with epilepsy.

Pisu M, Richman J, Szaflarski JP, Funkhouser E, Dai C, Juarez L, Faught E, Martin RC.

Epilepsia. 2019 Jul;60(7):1462-1471. doi: 10.1111/epi.16051. Epub 2019 Jun 6.

PMID:
31169918
11.

fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy.

Allendorfer JB, Nenert R, Bebin EM, Gaston TE, Grayson LE, Hernando KA, Houston JT, Hansen B, Szaflarski JP.

Epilepsy Behav. 2019 Jul;96:114-121. doi: 10.1016/j.yebeh.2019.04.008. Epub 2019 May 24.

PMID:
31129526
12.

A pilot study of combined endurance and resistance exercise rehabilitation for verbal memory and functional connectivity improvement in epilepsy.

Allendorfer JB, Brokamp GA, Nenert R, Szaflarski JP, Morgan CJ, Tuggle SC, Ver Hoef L, Martin RC, Szaflarski BA, Kaur M, Lahti AC, Bamman MM.

Epilepsy Behav. 2019 Jul;96:44-56. doi: 10.1016/j.yebeh.2019.04.020. Epub 2019 May 9.

PMID:
31078935
13.

Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.

Szaflarski JP, Hernando K, Bebin EM, Gaston TE, Grayson LE, Ampah SB, Moreadith R.

Epilepsy Behav. 2019 Jun;95:131-136. doi: 10.1016/j.yebeh.2019.03.042. Epub 2019 Apr 29.

PMID:
31048098
14.

Neural response to stress and perceived stress differ in patients with left temporal lobe epilepsy.

Goodman AM, Allendorfer JB, Heyse H, Szaflarski BA, Eliassen JC, Nelson EB, Storrs JM, Szaflarski JP.

Hum Brain Mapp. 2019 Aug 15;40(12):3415-3430. doi: 10.1002/hbm.24606. Epub 2019 Apr 29.

PMID:
31033120
15.

Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.

Laux LC, Bebin EM, Checketts D, Chez M, Flamini R, Marsh ED, Miller I, Nichol K, Park Y, Segal E, Seltzer L, Szaflarski JP, Thiele EA, Weinstock A; CBD EAP study group.

Epilepsy Res. 2019 Aug;154:13-20. doi: 10.1016/j.eplepsyres.2019.03.015. Epub 2019 Mar 25.

16.

Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.

Gaston TE, Szaflarski M, Hansen B, Bebin EM, Szaflarski JP; UAB CBD Program.

Epilepsy Behav. 2019 Jun;95:10-17. doi: 10.1016/j.yebeh.2019.03.035. Epub 2019 Apr 16.

PMID:
31003195
17.

Ictogenesis during sEEG evaluation after acute intracranial hemorrhage.

Issa Roach AT, Pizarro D, Deshpande HD, Pati S, Szaflarski JP, Riley KO, Muhlhofer W, Houston T.

Epilepsy Behav Case Rep. 2019 Mar 7;11:115-119. doi: 10.1016/j.ebcr.2019.02.001. eCollection 2019.

18.

Duration of therapeutic coma and outcome of refractory status epilepticus.

Muhlhofer WG, Layfield S, Lowenstein D, Lin CP, Johnson RD, Saini S, Szaflarski JP.

Epilepsia. 2019 May;60(5):921-934. doi: 10.1111/epi.14706. Epub 2019 Apr 7.

19.

The Dilemma of the Chicken or the Egg-What Appears First in TLE-Seizures or Morphometric Changes in the Temporal Lobe?

Szaflarski JP.

Epilepsy Curr. 2019 Mar-Apr;19(2):101-102. doi: 10.1177/1535759719835675.

20.

Cortical excitability affects mood state in patients with idiopathic generalized epilepsies (IGEs).

Bolden LB, Griffis JC, Nenert R, Allendorfer JB, Szaflarski JP.

Epilepsy Behav. 2019 Jan;90:84-89. doi: 10.1016/j.yebeh.2018.11.001. Epub 2018 Dec 2.

PMID:
30517908
21.

The Highs and Lows of the Endocannabinoid System-Another Piece to the Epilepsy Puzzle?

Szaflarski JP.

Epilepsy Curr. 2018 Sep-Oct;18(5):315-317. doi: 10.5698/1535-7597.18.5.315. No abstract available.

22.

The US Food and Drug Administration's Authorization of the First Cannabis-Derived Pharmaceutical: Are We Out of the Haze?

Yang YT, Szaflarski JP.

JAMA Neurol. 2019 Feb 1;76(2):135-136. doi: 10.1001/jamaneurol.2018.3550. No abstract available.

PMID:
30452525
23.

Cortical excitability and seizure control influence attention performance in patients with idiopathic generalized epilepsies (IGEs).

Bolden LB, Griffis JC, Nenert R, Allendorfer JB, Szaflarski JP.

Epilepsy Behav. 2018 Dec;89:135-142. doi: 10.1016/j.yebeh.2018.10.026. Epub 2018 Nov 8.

PMID:
30415135
24.

Psychogenic Nonepileptic Seizures (PNES) as a Network Disorder - Evidence From Neuroimaging of Functional (Psychogenic) Neurological Disorders.

Szaflarski JP, LaFrance WC Jr.

Epilepsy Curr. 2018 Jul-Aug;18(4):211-216. doi: 10.5698/1535-7597.18.4.211. No abstract available.

25.

Bilateral independent periodic discharges are associated with electrographic seizures and poor outcome: A case-control study.

Osman G, Rahangdale R, Britton JW, Gilmore EJ, Haider HA, Hantus S, Herlopian A, Hocker SE, Woo Lee J, Legros B, Mendoza M, Punia V, Rampal N, Szaflarski JP, Wallace AD, Westover MB, Hirsch LJ, Gaspard N.

Clin Neurophysiol. 2018 Nov;129(11):2284-2289. doi: 10.1016/j.clinph.2018.07.025. Epub 2018 Aug 29.

26.

Cannabis for the Treatment of Epilepsy: an Update.

Gaston TE, Szaflarski JP.

Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y. Review.

PMID:
30194563
27.

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program.

Epilepsy Behav. 2018 Oct;87:131-136. doi: 10.1016/j.yebeh.2018.07.020. Epub 2018 Aug 9.

28.

Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.

Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT, Friedman D.

Epilepsy Behav. 2018 Sep;86:131-137. doi: 10.1016/j.yebeh.2018.05.013. Epub 2018 Jul 11.

29.

Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.

Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons PD, Zentil PP, Wechsler R; CBD EAP study group.

Epilepsia. 2018 Aug;59(8):1540-1548. doi: 10.1111/epi.14477. Epub 2018 Jul 12.

30.

Toward the "Fingerprint" of the Ictal Onset Zone - Is Mr. Morlet the Winner?

Szaflarski JP, Toth E.

Epilepsy Curr. 2018 May-Jun;18(3):158-159. doi: 10.5698/1535-7597.18.3.158. No abstract available.

31.

A feasibility study of combined intermittent theta burst stimulation and modified constraint-induced aphasia therapy in chronic post-stroke aphasia.

Szaflarski JP, Griffis J, Vannest J, Allendorfer JB, Nenert R, Amara AW, Sung V, Walker HC, Martin AN, Mark VW, Zhou X.

Restor Neurol Neurosci. 2018;36(4):503-518. doi: 10.3233/RNN-180812.

PMID:
29889086
32.

Affiliate stigma and caregiver burden in intractable epilepsy.

Hansen B, Szaflarski M, Bebin EM, Szaflarski JP.

Epilepsy Behav. 2018 Aug;85:1-6. doi: 10.1016/j.yebeh.2018.05.028. Epub 2018 Jun 7.

PMID:
29886019
33.

The Disruptive Nature of Focal Developmental Insults.

Szaflarski JP.

Epilepsy Curr. 2018 Jan-Feb;18(1):29-30. doi: 10.5698/1535-7597.18.1.29. No abstract available.

34.

Longitudinal fMRI study of language recovery after a left hemispheric ischemic stroke.

Nenert R, Allendorfer JB, Martin AM, Banks C, Vannest J, Holland SK, Hart KW, Lindsell CJ, Szaflarski JP.

Restor Neurol Neurosci. 2018;36(3):359-385. doi: 10.3233/RNN-170767.

PMID:
29782329
35.

Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 2: Effect on White Matter Integrity.

Barghi A, Allendorfer JB, Taub E, Womble B, Hicks JM, Uswatte G, Szaflarski JP, Mark VW.

Neurorehabil Neural Repair. 2018 Mar;32(3):233-241. doi: 10.1177/1545968317753073.

36.

How UV Light Touches the Brain and Endocrine System Through Skin, and Why.

Slominski AT, Zmijewski MA, Plonka PM, Szaflarski JP, Paus R.

Endocrinology. 2018 May 1;159(5):1992-2007. doi: 10.1210/en.2017-03230. Review.

37.

Prognostic Value of EEG in Patients after Cardiac Arrest-An Updated Review.

Muhlhofer W, Szaflarski JP.

Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):16. doi: 10.1007/s11910-018-0826-6. Review.

PMID:
29525975
38.

Risk of pharmacokinetic interactions between antiepileptic and other drugs in older persons and factors associated with risk.

Faught E, Szaflarski JP, Richman J, Funkhouser E, Martin RC, Piper K, Dai C, Juarez L, Pisu M.

Epilepsia. 2018 Mar;59(3):715-723. doi: 10.1111/epi.14010. Epub 2018 Feb 7.

39.

An interaction between warfarin and cannabidiol, a case report.

Grayson L, Vines B, Nichol K, Szaflarski JP; UAB CBD Program.

Epilepsy Behav Case Rep. 2017 Oct 12;9:10-11. doi: 10.1016/j.ebcr.2017.10.001. eCollection 2018.

40.

Facial emotion processing in patients with seizure disorders.

Szaflarski JP, Allendorfer JB, Nenert R, LaFrance WC Jr, Barkan HI, DeWolfe J, Pati S, Thomas AE, Ver Hoef L.

Epilepsy Behav. 2018 Feb;79:193-204. doi: 10.1016/j.yebeh.2017.12.004. Epub 2018 Jan 6.

PMID:
29309953
41.

Racial disparities in temporal lobe epilepsy.

Allen SE, Limdi N, Westrick AC, Ver Hoef LW, Szaflarski JP, Knowlton RC.

Epilepsy Res. 2018 Feb;140:56-60. doi: 10.1016/j.eplepsyres.2017.12.012. Epub 2017 Dec 16.

PMID:
29272743
42.

The 'Thalamic Hubness' of Anterior Temporal Lobectomy Outcome.

Szaflarski JP.

Epilepsy Curr. 2017 Sep-Oct;17(5):283-284. doi: 10.5698/1535-7597.17.5.283. No abstract available.

43.

Dysfunction in emotion processing underlies functional (psychogenic) dystonia.

Espay AJ, Maloney T, Vannest J, Norris MM, Eliassen JC, Neefus E, Allendorfer JB, Chen R, Szaflarski JP.

Mov Disord. 2018 Jan;33(1):136-145. doi: 10.1002/mds.27217. Epub 2017 Nov 10.

44.

Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study.

Espay AJ, Maloney T, Vannest J, Norris MM, Eliassen JC, Neefus E, Allendorfer JB, Lang AE, Szaflarski JP.

Neuroimage Clin. 2017 Oct 18;17:179-187. doi: 10.1016/j.nicl.2017.10.020. eCollection 2018.

45.

The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy.

Warren PP, Bebin EM, Nabors LB, Szaflarski JP.

Neurocase. 2017 Oct - Dec;23(5-6):287-291. doi: 10.1080/13554794.2017.1391294. Epub 2017 Oct 24.

PMID:
29063814
46.

Linking left hemispheric tissue preservation to fMRI language task activation in chronic stroke patients.

Griffis JC, Nenert R, Allendorfer JB, Szaflarski JP.

Cortex. 2017 Nov;96:1-18. doi: 10.1016/j.cortex.2017.08.031. Epub 2017 Sep 5.

47.

Relationship Between Alpha Rhythm and the Default Mode Network: An EEG-fMRI Study.

Bowman AD, Griffis JC, Visscher KM, Dobbins AC, Gawne TJ, DiFrancesco MW, Szaflarski JP.

J Clin Neurophysiol. 2017 Nov;34(6):527-533. doi: 10.1097/WNP.0000000000000411.

PMID:
28914659
48.

Age-related language lateralization assessed by fMRI: The effects of sex and handedness.

Nenert R, Allendorfer JB, Martin AM, Banks C, Vannest J, Holland SK, Szaflarski JP.

Brain Res. 2017 Nov 1;1674:20-35. doi: 10.1016/j.brainres.2017.08.021. Epub 2017 Aug 19.

PMID:
28830770
49.

Author response: Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Gloss D, Szaflarski JP, Holland SK, Binder JR, Theodore WH.

Neurology. 2017 Aug 8;89(6):640-641. doi: 10.1212/WNL.0000000000004203. No abstract available.

PMID:
28784637
50.

Interactions between cannabidiol and commonly used antiepileptic drugs.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program.

Epilepsia. 2017 Sep;58(9):1586-1592. doi: 10.1111/epi.13852. Epub 2017 Aug 6.

Supplemental Content

Loading ...
Support Center